The Tumor–Lymphatic–Lymph Node Axis in Immune Checkpoint Inhibitor Response and Resistance

Immune checkpoint inhibitors can produce durable tumor control, but their activity depends on immune processes extending beyond the tumor microenvironment. Lymphatic vessels and tumor-draining lymph nodes connect antigen release with dendritic-cell migration, T-cell priming, and the maintenance of progenitor populations capable of replenishing antitumor responses. The same network can promote deletional tolerance, regulatory-cell activity, and metastatic dissemination. This narrative review examines how these opposing functions influence checkpoint inhibitor response and resistance, with emphasis on the distinction between mechanistic evidence and clinical inference. Mouse studies establish roles for nodal dendritic cells, lymphatic endothelial PD-L1, and stem-like CD8+ T-cell reservoirs, while human tissue studies support related cellular and clonal relationships. VEGF-C illustrates the context dependence of this biology: lymphangiogenesis can enhance immune recruitment and checkpoint activity in some models while facilitating tolerance and metastasis in others. Surgery and nodal irradiation can interrupt immune communication, although compensatory drainage and treatment timing modify their effects. Randomized melanoma trials support neoadjuvant-inclusive checkpoint therapy, but do not establish lymph-node preservation as the mechanism of benefit. Candidate biomarkers integrating drainage, nodal architecture, dendritic-cell activity, and T-cell state remain investigational. Therapeutic development should therefore seek to preserve productive antigen presentation and immune-cell trafficking while controlling dissemination and suppressive signaling. Prospective studies with paired tumor, lymph-node, and blood sampling are needed before lymphatic measurements can guide patient selection or changes to established locoregional treatment.

Authors

Institutions

Publication Details

Journal
Lymphatics
Published
2026-11-18
DOI
https://doi.org/10.3390/lymphatics4040058
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Tumor–Lymphatic–Lymph Node Axis in Immune Checkpoint Inhibitor Response and Resistance

Yumna Khalid, Saad Abdul Kareem, Sree Manasa PuttamReddy
4 links
Lymphatics
Cancer Immunotherapy and Biomarkers
article

The Tumor–Lymphatic–Lymph Node Axis in Immune Checkpoint Inhibitor Response and Resistance

Yumna Khalid, Saad Abdul Kareem, Sree Manasa PuttamReddy
article en

Abstract

Immune checkpoint inhibitors can produce durable tumor control, but their activity depends on immune processes extending beyond the tumor microenvironment. Lymphatic vessels and tumor-draining lymph nodes connect antigen release with dendritic-cell migration, T-cell priming, and the maintenance of progenitor populations capable of replenishing antitumor responses. The same network can promote deletional tolerance, regulatory-cell activity, and metastatic dissemination. This narrative review examines how these opposing functions influence checkpoint inhibitor response and resistance, with emphasis on the distinction between mechanistic evidence and clinical inference. Mouse studies establish roles for nodal dendritic cells, lymphatic endothelial PD-L1, and stem-like CD8+ T-cell reservoirs, while human tissue studies support related cellular and clonal relationships. VEGF-C illustrates the context dependence of this biology: lymphangiogenesis can enhance immune recruitment and checkpoint activity in some models while facilitating tolerance and metastasis in others. Surgery and nodal irradiation can interrupt immune communication, although compensatory drainage and treatment timing modify their effects. Randomized melanoma trials support neoadjuvant-inclusive checkpoint therapy, but do not establish lymph-node preservation as the mechanism of benefit. Candidate biomarkers integrating drainage, nodal architecture, dendritic-cell activity, and T-cell state remain investigational. Therapeutic development should therefore seek to preserve productive antigen presentation and immune-cell trafficking while controlling dissemination and suppressive signaling. Prospective studies with paired tumor, lymph-node, and blood sampling are needed before lymphatic measurements can guide patient selection or changes to established locoregional treatment.

LymphaticsVol. 4(4)
University of Maryland, Baltimore (US), University of Maryland Medical Center (US)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon